Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimitespib - Taiho Pharmaceutical

Drug Profile

Pimitespib - Taiho Pharmaceutical

Alternative Names: Jeselhy; TAS 116

Latest Information Update: 14 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics; Benzamides; Imidazoles; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastrointestinal stromal tumours
  • Phase II Prostate cancer
  • Phase I Solid tumours

Most Recent Events

  • 08 Nov 2023 Phase-II clinical trials in Prostate cancer in Japan after June 2023 (PO) (Otsuka Pharmaceutical pipeline, November 2023)
  • 20 Oct 2023 Efficacy and adverse events data from a phase I CHAPTER-GIST-101 trial in Gastrointestinal stromal tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 30 Aug 2022 Launched for Gastrointestinal stromal tumours (Late-stage disease, Second-line therapy or greater) in Japan (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top